DENN domain containing 6AGenealiases: AFI1A · FAM116A
Q-omics provides the consensus-scored DENND6A profile across patient tissues and cancer cell-line models. DENND6A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DENND6A is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, DENND6A RNA expression shows 20,834 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where DENND6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND6A survival associations across molecular data types. DENND6A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND6A RNA expression–survival associations across cancer types. High DENND6A expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in KIRC, BRCA and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DENND6A RNA expression.
This table summarizes DENND6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DENND6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND6A shows lower tumor expression in THCA, KICH, LUAD and UCEC and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher DENND6A RNA expression in normal versus tumor tissue (log2 FC = −1.887, t-test p < 0.001).
This table shows molecular features associated with DENND6A in patient tissues and cancer cell lines. In patient samples, DENND6A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
